IL161083A0 - Conjugated psychotropic drugs and uses thereof - Google Patents

Conjugated psychotropic drugs and uses thereof

Info

Publication number
IL161083A0
IL161083A0 IL16108302A IL16108302A IL161083A0 IL 161083 A0 IL161083 A0 IL 161083A0 IL 16108302 A IL16108302 A IL 16108302A IL 16108302 A IL16108302 A IL 16108302A IL 161083 A0 IL161083 A0 IL 161083A0
Authority
IL
Israel
Prior art keywords
residue
chemical moiety
psychotic drug
psychotropic drugs
organic acid
Prior art date
Application number
IL16108302A
Other languages
English (en)
Original Assignee
Univ Ramot
Univ Bar Ilan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Univ Bar Ilan filed Critical Univ Ramot
Publication of IL161083A0 publication Critical patent/IL161083A0/xx
Priority to IL202291A priority Critical patent/IL202291A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Cephalosporin Compounds (AREA)
IL16108302A 2001-09-27 2002-09-29 Conjugated psychotropic drugs and uses thereof IL161083A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL202291A IL202291A0 (en) 2001-09-27 2009-11-23 Conjugated psychotropic drugs and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32493601P 2001-09-27 2001-09-27
PCT/IL2002/000795 WO2003026563A2 (en) 2001-09-27 2002-09-29 Conjugated anti-psychotic drugs and uses thereof

Publications (1)

Publication Number Publication Date
IL161083A0 true IL161083A0 (en) 2004-08-31

Family

ID=23265759

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16108302A IL161083A0 (en) 2001-09-27 2002-09-29 Conjugated psychotropic drugs and uses thereof
IL202291A IL202291A0 (en) 2001-09-27 2009-11-23 Conjugated psychotropic drugs and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL202291A IL202291A0 (en) 2001-09-27 2009-11-23 Conjugated psychotropic drugs and uses thereof

Country Status (10)

Country Link
EP (2) EP1429844B1 (ko)
JP (3) JP4521187B2 (ko)
KR (4) KR101238452B1 (ko)
CN (2) CN100558365C (ko)
AT (1) ATE541588T1 (ko)
CA (1) CA2461663A1 (ko)
ES (2) ES2399977T3 (ko)
IL (2) IL161083A0 (ko)
MX (1) MXPA04002912A (ko)
WO (1) WO2003026563A2 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE541588T1 (de) * 2001-09-27 2012-02-15 Univ Ramot Konjugat von perphenazin und gaba und seine verwendungen
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20090298814A1 (en) * 2005-06-07 2009-12-03 Ramot At Tel Aviv Univeristy Ltd Novel salts of conjugated psychotropic drugs and processes of preparing same
CN101247837B (zh) * 2005-06-07 2013-03-20 特拉维夫大学拉莫特有限公司 新的轭合精神活性药物的盐及其制备方法
ES2365897T3 (es) * 2006-06-22 2011-10-13 Ramot, At Tel Aviv University Ltd. Nuevos inhibidores de la recaptación de serotonina como fármacos que tienen actividad limitada al sistema periférico.
US9278947B2 (en) 2006-06-22 2016-03-08 Ramot At Tel-Aviv University Ltd. Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
EP2051735B1 (en) * 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
MX2009005676A (es) * 2006-11-30 2010-03-22 Cenerx Biopharma Inc Dialquilamino alquil esteres de pivagabina como medicamentos para el tratamiento de alteraciones del sistema nervioso central.
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
CN102131791B (zh) 2008-06-20 2014-12-24 阿斯利康(瑞典)有限公司 二苯并硫杂氮杂*衍生物及其用途
US8268887B2 (en) * 2008-10-08 2012-09-18 Feng Xu Drug conjugates and methods of use thereof
MX2012006566A (es) 2009-12-09 2012-11-29 Univ Ramot Metodo para mejorar las funciones cognoscitivas.
AU2014202425B2 (en) * 2009-12-31 2015-11-19 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
CN102781236B (zh) 2009-12-31 2015-01-07 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
US8377929B2 (en) 2010-02-24 2013-02-19 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same
WO2011112657A1 (en) * 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
CN111329865A (zh) * 2020-03-30 2020-06-26 华东理工大学 奋乃静在制备治疗子宫内膜癌的药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE568837A (ko) 1957-09-11 1900-01-01
US3194733A (en) * 1961-04-26 1965-07-13 Olin Mathicson Chemical Corp Phenothiazine compositions and method of treating mental disorders
GB1460713A (en) * 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US3978216A (en) 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US3956493A (en) * 1974-10-21 1976-05-11 E. R. Squibb & Sons, Inc. Long acting tranquilizing agent
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
GB1540842A (en) * 1976-08-25 1979-02-14 Kefalas As Phenothiazines
US5525727A (en) * 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
CN1375287A (zh) * 2001-03-16 2002-10-23 王玉万 含氯氰碘柳胺或其钠盐的兽用混悬注射剂
ATE541588T1 (de) * 2001-09-27 2012-02-15 Univ Ramot Konjugat von perphenazin und gaba und seine verwendungen

Also Published As

Publication number Publication date
ES2379544T3 (es) 2012-04-27
WO2003026563A2 (en) 2003-04-03
KR20100097224A (ko) 2010-09-02
KR20120032547A (ko) 2012-04-05
WO2003026563A9 (en) 2004-04-22
CN100558365C (zh) 2009-11-11
KR101238452B1 (ko) 2013-02-28
IL202291A0 (en) 2011-07-31
KR20090130150A (ko) 2009-12-17
ATE541588T1 (de) 2012-02-15
JP2014015472A (ja) 2014-01-30
EP1429844B1 (en) 2012-01-18
EP2275143A3 (en) 2011-01-26
CN1596141A (zh) 2005-03-16
JP2005503423A (ja) 2005-02-03
WO2003026563A3 (en) 2004-03-18
EP1429844A2 (en) 2004-06-23
JP4521187B2 (ja) 2010-08-11
MXPA04002912A (es) 2004-07-05
ES2399977T3 (es) 2013-04-04
EP1429844A4 (en) 2006-06-07
JP2010090170A (ja) 2010-04-22
EP2275143A2 (en) 2011-01-19
EP2275143B1 (en) 2012-12-19
CN101445494A (zh) 2009-06-03
KR20040062554A (ko) 2004-07-07
KR100996239B1 (ko) 2010-11-23
CA2461663A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
IL202291A0 (en) Conjugated psychotropic drugs and uses thereof
EP2269657A3 (en) Prodrugs containing novel bio-cleavable linkers
KR930019680A (ko) 티에노 [3,2-b]피리딘 유도체
HU229581B1 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
DE60329210D1 (en) Camptothecin-carboxylat-formulierungen
ATE348608T1 (de) Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne
HK1057859A1 (en) Highly concentrated stable meloxicam solutions
IL157701A0 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
WO2006131923A3 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
MA27576A1 (fr) Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
AU9001791A (en) Stable agrochemical compositions
ATE275572T1 (de) Malto-oligosaccharid-derivate und ihre anwendungen
BR0115075A (pt) Benzo'b!tiofenos e benzo'd!isotiazóis para baixamento de colesterol
AU2408602A (en) Indole derivatives and use thereof in medicines
MY122570A (en) Benzamide derivatives and drugs containing the same
PH31171A (en) Aminobenzonic acid derivatives useful for treatinggastrointestinal conditions.
AU3595689A (en) Anthracycline derivatives having cytostatic activity
KR910002450A (ko) 당뇨병 치료용 제약 조성물
EP1222932A4 (en) ELECTROPORATION COMPOSITIONS
GEP20084307B (en) Use of 2h- [1, 3] - oxazino [3, 2-a] indole derivatives for the treatment of neuropathic pain
ZA200307067B (en) Antiproliferative agents.
TH43746A (th) อนุพันธ์ 3,4-ไดแอริลไธเอโซลิน-2-โอน หรือ -2-ไธโอนชนิดใหม่วิธีการเตรียมของสารเหล่านี้ และการใช้สารเหล่านี้ในการรักษาโรค
TH50173A (th) การใช้ 1-ไฮดรอกซี-2-ไพริโดนสำหรับการบำบัดการติดเชื้อที่ผิวหนัง
KR950016752A (ko) 피페라지닐 퀴놀론 카르복실산의 고농도 용액